Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

one year ago
Routine laboratory factors predict adverse pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy, according to a prospective, case control study.

ENABLEX Now Approved in Malaysia

2 years ago
Reclassification of MIMS Class – ENABLEX
In MIMS 140th edition (1st Issue 2015), there was an error classifying Enablex under 10f. Other Drugs Acting on the Genito-Urinary System. With effect from MIMS 141st edition (2nd Issue 2015), Enablex will be reclassified under 10e. Drugs for Bladder & Prostate Disorder to reflect a more accurate classification based on its therapeutic use.


ENABLEX – Darifenacin Hydrobromide 7.5mg Prolonged Release Tablet
 A highly selective M3 antagonist developed for treating overactive bladder (OAB) 1, 2
• Improves Incontinence Episodes (IEs) per week, Urgency Episodes (UEs) per day and micturitions per day in OAB patients with 5-50 episodes of incontinence per week 3
• No significant effect on heart rate 4
• Does not prolong the QT/QTc interval 5
• Does not impair memory or other cognitive functions 6
 
References:
1. KAY G, WESNES K. 2005. Pharmacodynamic effects if darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU International; 96:1055-62.
2. ENABLEX® Package Insert.
3. CHAPPLE C, STEERS W, NORTON P, MILLARD R, KRALIDIS G, GLAVIND K, et al. 2005. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU International; 95:993-1001.
4. OLSHANSKY B, EBINGER U, BRUM J, EGERMARK M, VIEGAS A, REKEDA L. 2008. Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants ≥50 Years. J Cardiovasc Pharmacol Ther; doi:10.1177/1074248408325404.
5. SERRA D, AFFRIME M, BEDIGIAN M, GREIG G, MILOSAVLJEV S, SKERJANEC A, et al. 2005. QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M3 Selective Receptor Antagonist for the Treatment of Overactive Bladder. J Clin Pharmacol ; 45:1038-1047
6. KAY G, EBINGER U. 2008. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract; 62(11):1792-1800.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

one year ago
Routine laboratory factors predict adverse pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy, according to a prospective, case control study.